Targeting Jak2 to improve treatment for advanced prostate cancer
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer
This study is looking at how blocking a specific signaling pathway might help make prostate cancer treatments work better for patients whose cancer has become resistant to hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11070397 on NIH RePORTER |
What this research studies
This research investigates how inhibiting Jak2 signaling can help overcome resistance to androgen receptor therapies in advanced prostate cancer. The approach focuses on understanding the mechanisms that keep androgen receptors active even after treatment, which contributes to the cancer's progression. By using new-generation Jak2 inhibitors, the research aims to reduce the expression of androgen receptors and their variants, potentially leading to more effective therapies for patients with castrate-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with castrate-resistant prostate cancer who have not responded to standard androgen deprivation therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer who currently have limited options.
How similar studies have performed: Other research has shown promise in targeting Jak2 signaling in cancer treatment, indicating that this approach may be viable.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Nevalainen, Marja T — Thomas Jefferson University
- Study coordinator: Nevalainen, Marja T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.